Cargando…
Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan
Hepatis virus C (HCV) infection causes liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. The objective of our study was to examine the effects of the HCV nonstructural protein (NS) 3/4A inhibitor glecaprevir/NS5A inhibitor pibrentasvir on real-world HCV patients in the northern part of T...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658140/ https://www.ncbi.nlm.nih.gov/pubmed/34884231 http://dx.doi.org/10.3390/jcm10235529 |
_version_ | 1784612659733200896 |
---|---|
author | Yamana, Yoichiro Kanda, Tatsuo Matsumoto, Naoki Honda, Masayuki Kumagawa, Mariko Sasaki, Reina Kanezawa, Shini Mizutani, Taku Yamagami, Hiroaki Masuzaki, Ryota Ishii, Tomotaka Nirei, Kazushige Moriyama, Mitsuhiko |
author_facet | Yamana, Yoichiro Kanda, Tatsuo Matsumoto, Naoki Honda, Masayuki Kumagawa, Mariko Sasaki, Reina Kanezawa, Shini Mizutani, Taku Yamagami, Hiroaki Masuzaki, Ryota Ishii, Tomotaka Nirei, Kazushige Moriyama, Mitsuhiko |
author_sort | Yamana, Yoichiro |
collection | PubMed |
description | Hepatis virus C (HCV) infection causes liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. The objective of our study was to examine the effects of the HCV nonstructural protein (NS) 3/4A inhibitor glecaprevir/NS5A inhibitor pibrentasvir on real-world HCV patients in the northern part of Tokyo, Japan. Although 106 patients were consecutively included, a total of 102 HCV-infected patients with chronic hepatitis or compensated cirrhosis, who received 8- or 12-week combination treatment with glecaprevir/pibrentasvir and were followed up to week 12 after the end of treatment were analyzed retrospectively. Only three patients discontinued treatment due to adverse events; however, they achieved a sustained virologic response at 12 weeks (SVR12). Finally, SVR rates were 99.0% (101/102). Only one patient without liver cirrhosis was a treatment relapser who received hepatic resection for HCC approximately two years after commencement of the 8-week combination treatment with glecaprevir/pibrentasvir. After the exclusion of patients with HCV genotype 1b and P32 deletion in the HCV NS5A region, a 12-week combination of glecaprevir/pibrentasvir led to SVR12 in all nine direct-acting antiviral-experienced patients. Glecaprevir/pibrentasvir had a high efficacy and an acceptable safety profile for real-world HCV patients in a single hospital in Japan. |
format | Online Article Text |
id | pubmed-8658140 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86581402021-12-10 Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan Yamana, Yoichiro Kanda, Tatsuo Matsumoto, Naoki Honda, Masayuki Kumagawa, Mariko Sasaki, Reina Kanezawa, Shini Mizutani, Taku Yamagami, Hiroaki Masuzaki, Ryota Ishii, Tomotaka Nirei, Kazushige Moriyama, Mitsuhiko J Clin Med Article Hepatis virus C (HCV) infection causes liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. The objective of our study was to examine the effects of the HCV nonstructural protein (NS) 3/4A inhibitor glecaprevir/NS5A inhibitor pibrentasvir on real-world HCV patients in the northern part of Tokyo, Japan. Although 106 patients were consecutively included, a total of 102 HCV-infected patients with chronic hepatitis or compensated cirrhosis, who received 8- or 12-week combination treatment with glecaprevir/pibrentasvir and were followed up to week 12 after the end of treatment were analyzed retrospectively. Only three patients discontinued treatment due to adverse events; however, they achieved a sustained virologic response at 12 weeks (SVR12). Finally, SVR rates were 99.0% (101/102). Only one patient without liver cirrhosis was a treatment relapser who received hepatic resection for HCC approximately two years after commencement of the 8-week combination treatment with glecaprevir/pibrentasvir. After the exclusion of patients with HCV genotype 1b and P32 deletion in the HCV NS5A region, a 12-week combination of glecaprevir/pibrentasvir led to SVR12 in all nine direct-acting antiviral-experienced patients. Glecaprevir/pibrentasvir had a high efficacy and an acceptable safety profile for real-world HCV patients in a single hospital in Japan. MDPI 2021-11-26 /pmc/articles/PMC8658140/ /pubmed/34884231 http://dx.doi.org/10.3390/jcm10235529 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yamana, Yoichiro Kanda, Tatsuo Matsumoto, Naoki Honda, Masayuki Kumagawa, Mariko Sasaki, Reina Kanezawa, Shini Mizutani, Taku Yamagami, Hiroaki Masuzaki, Ryota Ishii, Tomotaka Nirei, Kazushige Moriyama, Mitsuhiko Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan |
title | Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan |
title_full | Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan |
title_fullStr | Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan |
title_full_unstemmed | Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan |
title_short | Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan |
title_sort | efficacy of glecaprevir/pibrentasvir for real-world hcv infected patients in the northern part of tokyo, japan |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658140/ https://www.ncbi.nlm.nih.gov/pubmed/34884231 http://dx.doi.org/10.3390/jcm10235529 |
work_keys_str_mv | AT yamanayoichiro efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan AT kandatatsuo efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan AT matsumotonaoki efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan AT hondamasayuki efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan AT kumagawamariko efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan AT sasakireina efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan AT kanezawashini efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan AT mizutanitaku efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan AT yamagamihiroaki efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan AT masuzakiryota efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan AT ishiitomotaka efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan AT nireikazushige efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan AT moriyamamitsuhiko efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan |